In conclusion, the present study suggests that the adverse effect of reduced NME1 expression on RFS may be exacerbated by cisplatin-based adjuvant chemotherapy and β-catenin overexpression through other mechanisms rather than through the nuclear translocation of β-catenin in early stage NSCLC. This evidence concerns the gene NME1 and non-small cell lung carcinoma.